Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RESTASIS vs REVUMENIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RESTASIS vs REVUMENIB: Safety Overview

Metric RESTASIS REVUMENIB
Total FAERS Reports 1,158 371
Deaths Reported 0 49
Death Rate N/A 13.2%
Hospitalizations 5 93
Average Patient Age 66.9 yrs 46.4 yrs
% Female Patients N/A 47.6%
FDA Approval Date N/A Nov 15, 2024
Manufacturer N/A Syndax Pharmaceuticals, Inc.
Route N/A ORAL
Marketing Status N/A Prescription